Drug Trial Radar · NCT03827798
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
248
Actual
Start
Feb 27, 2019
Primary completion
Dec 4, 2024
Study completion Sep 11, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.
Conditions
- Hidradenitis Suppurativa
Interventions
CFZ533Drug
CFZ533 600 mg administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.
Placebo to CFZ533Drug
Placebo administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.
LYS006Drug
LYS006 20 mg administered orally twice per day until Week 16.
Placebo to LYS006Drug
Placebo administered orally twice per day until Week 16.
MAS825Drug
MAS825 300 mg administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.
Placebo to MAS825Drug
Placebo administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.
LOU064 25mgDrug
LOU064 25 mg administered orally twice per day until Week 16.
LOU064 100mgDrug
LOU064 100 mg administered orally twice per day until Week 16.
Placebo to LOU064Drug
Placebo administered orally twice per day until Week 16.
VAY736Drug
VAY736 300 mg administered s.c every 4 weeks until Week 13.
Placebo to VAY736Drug
Placebo administered s.c every 4 weeks until Week 13.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Clinical Response Measured by Simplified Hidradenitis Suppurativa (sHiSCR)Time frame: Baseline, Week 16
Locations
36 sites in 11 countries. Site status is shown where the registry gives one.
Olympian Clinical Research
Clearwater, Florida
Park Avenue Dermatology PA
Orange Park, Florida
University Of South Florida
Tampa, Florida
Advanced Medical Research
Sandy Springs, Georgia
NorthShore University Health System
Evanston, Illinois
Dawes Fretzin Clinical Rea Group
Indianapolis, Indiana
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania
Medical University of South Carolina MUSC
Charleston, South Carolina
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Roskilde, Denmark
Novartis Investigative Site
Antony, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Reims, France
Novartis Investigative Site
Rouen, France
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Schwerin, Germany
Novartis Investigative Site
Frankfurt, Germany, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Pécs, Baranya, Hungary
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site
Kopavogur, Iceland
Novartis Investigative Site
Groningen, Provincie Groningen, Netherlands
Novartis Investigative Site
Rotterdam, South Holland, Netherlands
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Las Palmas GC, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Granada, Andalusia, Spain
Novartis Investigative Site
Sabadell, Barcelona, Spain
Novartis Investigative Site
Manises, Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.